JP2007124901A - Method for extracting collagen - Google Patents
Method for extracting collagen Download PDFInfo
- Publication number
- JP2007124901A JP2007124901A JP2005317834A JP2005317834A JP2007124901A JP 2007124901 A JP2007124901 A JP 2007124901A JP 2005317834 A JP2005317834 A JP 2005317834A JP 2005317834 A JP2005317834 A JP 2005317834A JP 2007124901 A JP2007124901 A JP 2007124901A
- Authority
- JP
- Japan
- Prior art keywords
- centrifugation
- washing
- supernatant
- dialysis
- salting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 51
- 102000008186 Collagen Human genes 0.000 title abstract description 22
- 108010035532 Collagen Proteins 0.000 title abstract description 22
- 229920001436 collagen Polymers 0.000 title abstract description 20
- 239000006228 supernatant Substances 0.000 claims abstract description 57
- 239000002244 precipitate Substances 0.000 claims abstract description 48
- 238000000502 dialysis Methods 0.000 claims abstract description 46
- 230000029087 digestion Effects 0.000 claims abstract description 42
- 238000005185 salting out Methods 0.000 claims abstract description 38
- 239000008280 blood Substances 0.000 claims abstract description 30
- 210000004369 blood Anatomy 0.000 claims abstract description 30
- 102000057297 Pepsin A Human genes 0.000 claims abstract description 26
- 108090000284 Pepsin A Proteins 0.000 claims abstract description 26
- 229940111202 pepsin Drugs 0.000 claims abstract description 26
- 238000000926 separation method Methods 0.000 claims abstract description 25
- 238000000605 extraction Methods 0.000 claims abstract description 23
- 241000282414 Homo sapiens Species 0.000 claims abstract description 20
- 239000007853 buffer solution Substances 0.000 claims abstract description 12
- 239000003513 alkali Substances 0.000 claims abstract description 11
- 239000003929 acidic solution Substances 0.000 claims abstract description 6
- 238000005119 centrifugation Methods 0.000 claims description 95
- 238000005406 washing Methods 0.000 claims description 82
- 102000001187 Collagen Type III Human genes 0.000 claims description 32
- 108010069502 Collagen Type III Proteins 0.000 claims description 32
- 102000012422 Collagen Type I Human genes 0.000 claims description 29
- 108010022452 Collagen Type I Proteins 0.000 claims description 29
- 239000000872 buffer Substances 0.000 claims description 17
- 210000000577 adipose tissue Anatomy 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 11
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 6
- 102000035195 Peptidases Human genes 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims 2
- 238000002316 cosmetic surgery Methods 0.000 abstract description 10
- 239000000243 solution Substances 0.000 abstract description 10
- 238000004140 cleaning Methods 0.000 abstract description 9
- 206010011409 Cross infection Diseases 0.000 abstract description 5
- 206010029803 Nosocomial infection Diseases 0.000 abstract description 5
- 230000005923 long-lasting effect Effects 0.000 abstract description 2
- VVBXXVAFSPEIJQ-CVIPOMFBSA-N [(2r)-3-[[(2r)-1-[[(2s,5r,8r,11r,12s,15s,18s,21s)-15-[3-(diaminomethylideneamino)propyl]-21-hydroxy-5-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-2-(2-methylpropyl)-3,6,9,13,16,22-hexaoxo-8-propan-2-yl-10-oxa-1,4,7,14,17-pentazabicyclo[16.3.1]docosan-12-yl]am Chemical compound C([C@@H]1C(=O)N[C@@H](C(=O)O[C@H](C)[C@@H](C(N[C@@H](CCCN=C(N)N)C(=O)N[C@H]2CC[C@H](O)N(C2=O)[C@@H](CC(C)C)C(=O)N1C)=O)NC(=O)[C@H](NC(=O)[C@H](O)COS(O)(=O)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 VVBXXVAFSPEIJQ-CVIPOMFBSA-N 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 238000005199 ultracentrifugation Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000001962 electrophoresis Methods 0.000 description 8
- 229920000136 polysorbate Polymers 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000002033 PVDF binder Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000000503 Collagen Type II Human genes 0.000 description 4
- 108010041390 Collagen Type II Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000501 collagen implant Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 238000007443 liposuction Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
本発明は、形成外科や美容外科などの領域において用いられるI型及びIII型コラーゲンの抽出方法に関する。特に、人体に安心して使用できるようにする為、人体より採取した脂肪組織からI型及びIII型コラーゲンを抽出する方法に関する。 The present invention relates to a method for extracting type I and type III collagen used in areas such as plastic surgery and cosmetic surgery. In particular, the present invention relates to a method for extracting type I and type III collagen from adipose tissue collected from the human body so that the human body can use it with peace of mind.
ヒトの皮膚を構成しているコラーゲンは、主に、I型コラーゲンとIII型コラーゲンである。
現在、形成外科や美容外科などの領域において、顔面の皺や瘢痕の修正にZyderm(米国コラーゲン社製のコラーゲン注入剤)等の皮膚修正用皮下注入型コラーゲン製剤が広く用いられている。
Collagens constituting human skin are mainly type I collagen and type III collagen.
Currently, in the fields of plastic surgery and cosmetic surgery, subcutaneous injection type collagen preparations for skin correction such as Zyderm (collagen injection agent manufactured by Collagen USA) are widely used for correction of facial wrinkles and scars.
さて、前記皮膚修正用皮下注入型コラーゲン製剤(Zyderm)は、牛皮由来のコラーゲンをペプシンで処理し、コラーゲンの大部分の抗原性を有しているテロペプチド部分を除去した抗原性の弱いアテロコラーゲンである。そして、このコラーゲンをリン酸緩衝生理食塩水に分散し、無痛化剤としてリドカインを0.3%の割合で添加した粘性を有する乳白色のゲル状物質である。 The subcutaneous injection type collagen preparation for skin correction (Zyderm) is a weakly antigenic atelocollagen obtained by treating bovine skin-derived collagen with pepsin and removing most of the antigenic telopeptide portion of collagen. is there. This collagen is a milky white gel substance having a viscosity in which the collagen is dispersed in phosphate buffered saline and lidocaine is added at a rate of 0.3% as a soothing agent.
ところで、上記のコラーゲン製剤は、牛などの動物由来のものであることから、免疫原性や交差感染の危険性を有している。 By the way, since the above-mentioned collagen preparation is derived from animals such as cattle, it has immunogenicity and risk of cross infection.
そこで、ヒト由来の皮膚を一部採取し、培養操作によって皮膚由来の細胞を増殖し、注入剤として用いることが提案されている。 Thus, it has been proposed to collect a part of human-derived skin, proliferate the skin-derived cells by a culture operation, and use it as an injection.
しかしながら、この提案の技術は、患者の健常部の皮膚への浸襲を伴い、かつ、培養操作を必要とすることから、時間やコストが掛かる問題点が有る。 However, this proposed technique involves the invasion of the skin of the healthy part of the patient and requires a culturing operation, so that there is a problem that it takes time and cost.
さて、形成外科や美容外科などの領域において、組織増大術の一手法として、遊離脂肪移植手術や吸引脂肪注入術が提案されている。 In the fields of plastic surgery and cosmetic surgery, free fat transplantation and aspiration fat injection have been proposed as techniques for tissue augmentation.
これは、自家移植であり、交差感染などの危険性が無い。しかしながら、生着率が低く、効果も長続きしないと指摘されている。 This is an autograft and there is no risk of cross infection. However, it has been pointed out that the survival rate is low and the effects do not last long.
従って、本発明が解決しようとする課題は、上記の問題点を解決することである。すなわち、交差感染の恐れも無く、かつ、生着率が高く、効果も長続きする形成外科や美容外科などの領域において使用されるヒト由来のI型またはIII型コラーゲンを提供することである。 Therefore, the problem to be solved by the present invention is to solve the above problems. That is, it is to provide human-derived type I or type III collagen that is used in areas such as plastic surgery and cosmetic surgery where there is no risk of cross-infection, high survival rate, and long-lasting effects.
前記の課題は、ヒト脂肪組織をタンパク分解酵素で消化させる消化工程Cと、
消化工程C後における上清に遠心分離操作を施す遠心分離工程Dと、
遠心分離工程D後における上清に透析操作を施す透析工程Eと、
透析工程E後に遠心分離操作を施して得られる沈殿物に酸を添加して遠心分離操作を施す遠心分離工程Fと、
遠心分離工程F後における上清に対して塩析操作を施して得られた沈殿物を洗浄後に遠心分離操作を施す遠心分離工程Gと、
遠心分離工程G後における上清に透析操作を施す透析工程H
とを具備することを特徴とするI型コラーゲン抽出方法によって解決される。
The subject is a digestion step C for digesting human adipose tissue with a proteolytic enzyme,
Centrifugation step D for subjecting the supernatant after the digestion step C to a centrifugation operation,
Dialysis step E for dialysis operation on the supernatant after centrifugation step D,
Centrifugation step F, in which an acid is added to the precipitate obtained by centrifuging after the dialysis step E, and the centrifuging operation is performed.
Centrifugation step G in which the precipitate obtained by subjecting the supernatant after centrifugation step F to salting-out operation is subjected to centrifugation operation after washing,
Dialysis step H in which the supernatant after the centrifugation step G is dialyzed
It is solved by the type I collagen extraction method characterized by comprising.
特に、前記I型コラーゲン抽出方法であって、前記遠心分離工程Gは、
遠心分離工程F後における上清に緩衝液を添加すると共にアルカリを添加してpHが弱アルカリ状態にて塩析操作を施す塩析工程Gaと、
塩析工程Ga後における沈殿物を洗浄し、そして遠心分離操作を施して得られた沈殿物を緩衝液で洗浄する洗浄工程Gbと、
洗浄工程Gb後において遠心分離操作を施す遠心分離工程Gc
とを具備することを特徴とするI型コラーゲン抽出方法によって解決される。
In particular, in the type I collagen extraction method, the centrifugation step G includes:
A salting-out step Ga for adding a buffer solution to the supernatant after the centrifugal separation step F and adding an alkali to perform a salting-out operation in a weakly alkaline state;
A washing step Gb for washing the precipitate after the salting-out step Ga, and washing the precipitate obtained by centrifuging with a buffer;
Centrifugation step Gc for performing a centrifugal separation operation after the washing step Gb
It is solved by the type I collagen extraction method characterized by comprising.
又、前記I型コラーゲン抽出方法であって、
消化工程Cの前に脱血液処理を行う脱血液工程Aを更に具備する
ことを特徴とするI型コラーゲン抽出方法によって解決される。
In addition, the type I collagen extraction method,
The method is solved by a type I collagen extraction method, further comprising a blood removal step A for performing blood removal treatment before the digestion step C.
又、前記I型コラーゲン抽出方法であって、
消化工程Cの前に脱血液処理を行う脱血液工程Aと、
前記脱血液工程Aの後で、消化工程Cの前に脱脂肪処理を行う脱脂肪処理工程B
とを更に具備することを特徴とするI型コラーゲン抽出方法によって解決される。
In addition, the type I collagen extraction method,
A blood removal step A for performing blood removal treatment before the digestion step C;
A defatting process B for performing a defatting process after the blood removal process A and before the digestion process C
It is solved by the type I collagen extraction method characterized by further comprising.
中でも、ヒト脂肪組織をホモジナイズし、含まれている血液を略除去洗浄する洗浄工程Aaと、
前記洗浄工程Aaの後、タンパク分解酵素阻害剤を含有する酸性溶液で洗浄する洗浄工程Abと、
前記洗浄工程Abの後、有機溶媒を用いて含まれている脂肪分を除去する脱脂肪処理工程Bと、
前記脱脂肪処理工程Bの後、脂肪分が除去された残物にペプシンを加えてペプシン消化を施すペプシン消化工程Cと、
前記ペプシン消化工程C後における可溶上清に遠心分離操作を施す遠心分離工程Dと、
前記遠心分離工程D後における上清に透析操作を施す透析工程Eと、
前記透析工程E後に遠心分離操作を施して得られる沈殿物に酸を添加して遠心分離操作を施す遠心分離工程Fと、
前記遠心分離工程F後における上清に緩衝液を添加すると共にアルカリを添加してpHが7〜8にて塩析操作を施す塩析工程Gaと、
前記塩析工程Ga後における沈殿物を洗浄し、そして遠心分離操作を施して得られた沈殿物を緩衝液で洗浄する洗浄工程Gbと、
前記洗浄工程Gb後において遠心分離操作を施す遠心分離工程Gcと、
前記遠心分離工程Gc後における上清に透析操作を施す透析工程H
とを具備することを特徴とするI型コラーゲン抽出方法によって解決される。
Among them, a washing step Aa for homogenizing human adipose tissue and substantially removing and washing the contained blood,
After the washing step Aa, a washing step Ab for washing with an acidic solution containing a protease inhibitor;
After the washing step Ab, a defatting treatment step B for removing fat contained using an organic solvent,
Pepsin digestion step C, in which pepsin is added to the residue from which fat has been removed and pepsin digestion is performed after the fat removal treatment step B;
A centrifugation step D for subjecting the soluble supernatant after the pepsin digestion step C to a centrifugation operation;
A dialysis step E in which a dialysis operation is performed on the supernatant after the centrifugation step D;
Centrifugation step F in which an acid is added to a precipitate obtained by performing a centrifugation operation after the dialysis step E to perform a centrifugation operation;
A salting-out step Ga in which a buffer solution is added to the supernatant after the centrifugation step F and an alkali is added to perform a salting-out operation at a pH of 7-8;
A washing step Gb for washing the precipitate after the salting-out step Ga, and washing the precipitate obtained by centrifuging with a buffer;
A centrifugal separation step Gc for performing a centrifugal separation operation after the washing step Gb;
Dialysis step H in which the supernatant after the centrifugation step Gc is dialyzed
It is solved by the type I collagen extraction method characterized by comprising.
又、前記の課題は、ヒト脂肪組織をタンパク分解酵素で消化させる消化工程Cと、
消化工程C後における上清に遠心分離操作を施す遠心分離工程Dと、
遠心分離工程D後における上清に透析操作を施す透析工程Eと、
透析工程E後に遠心分離操作を施して得られる沈殿物に酸を添加して遠心分離操作を施す遠心分離工程Fと、
遠心分離工程F後における上清に対して塩析操作を施して得られた沈殿物を洗浄後に遠心分離操作を施す遠心分離工程Gと、
遠心分離工程G後における沈殿物を洗浄後、遠心分離操作を施し、そして上清に透析操作を施す透析工程I
とを具備することを特徴とするIII型コラーゲン抽出方法によって解決される。
Further, the above-mentioned problem is a digestion step C for digesting human adipose tissue with a proteolytic enzyme,
Centrifugation step D for subjecting the supernatant after the digestion step C to a centrifugation operation,
Dialysis step E for dialysis operation on the supernatant after centrifugation step D,
Centrifugation step F, in which an acid is added to the precipitate obtained by centrifuging after the dialysis step E, and the centrifuging operation is performed.
Centrifugation step G in which the precipitate obtained by subjecting the supernatant after centrifugation step F to salting-out operation is subjected to centrifugation operation after washing,
After washing the precipitate after the centrifugation step G, the centrifugation operation is performed, and the supernatant is dialyzed.
It is solved by the type III collagen extraction method characterized by comprising.
特に、前記III型コラーゲン抽出方法であって、前記遠心分離工程Gは、
遠心分離工程F後における上清に緩衝液を添加すると共にアルカリを添加してpHが弱アルカリ状態にて塩析操作を施す塩析工程Gaと、
塩析工程Ga後における沈殿物を洗浄し、そして遠心分離操作を施して得られた沈殿物を緩衝液で洗浄する洗浄工程Gbと、
洗浄工程Gb後において遠心分離操作を施す遠心分離工程Gc
とを具備することを特徴とするIII型コラーゲン抽出方法によって解決される。
In particular, in the method for extracting type III collagen, the centrifugation step G includes:
A salting-out step Ga for adding a buffer solution to the supernatant after the centrifugal separation step F and adding an alkali to perform a salting-out operation in a weakly alkaline state;
A washing step Gb for washing the precipitate after the salting-out step Ga, and washing the precipitate obtained by centrifuging with a buffer;
Centrifugation step Gc for performing a centrifugal separation operation after the washing step Gb
It is solved by the type III collagen extraction method characterized by comprising.
又、前記III型コラーゲン抽出方法であって、
消化工程Cの前に脱血液処理を行う脱血液工程Aを更に具備する
ことを特徴とするIII型コラーゲン抽出方法によって解決される。
The type III collagen extraction method,
This is solved by a type III collagen extraction method further comprising a blood removal step A in which blood removal treatment is performed before the digestion step C.
又、前記III型コラーゲン抽出方法であって、
消化工程Cの前に脱血液処理を行う脱血液工程Aと、
前記脱血液工程Aの後で、消化工程Cの前に脱脂肪処理を行う脱脂肪処理工程B
とを更に具備することを特徴とするIII型コラーゲン抽出方法によって解決される。
The type III collagen extraction method,
A blood removal step A for performing blood removal treatment before the digestion step C;
A defatting process B for performing a defatting process after the blood removal process A and before the digestion process C
It is solved by the type III collagen extraction method characterized by further comprising.
中でも、ヒト脂肪組織をホモジナイズし、含まれている血液を略除去洗浄する洗浄工程Aaと、
前記洗浄工程Aaの後、タンパク分解酵素阻害剤を含有する酸性溶液で洗浄する洗浄工程Abと、
前記洗浄工程Abの後、有機溶媒を用いて含まれている脂肪分を除去する脱脂肪処理工程Bと、
前記脱脂肪処理工程Bの後、脂肪分が除去された残物にペプシンを加えてペプシン消化を施すペプシン消化工程Cと、
前記ペプシン消化工程C後における可溶上清に遠心分離操作を施す遠心分離工程Dと、
前記遠心分離工程D後における上清に透析操作を施す透析工程Eと、
前記透析工程E後に遠心分離操作を施して得られる沈殿物に酸を添加して遠心分離操作を施す遠心分離工程Fと、
前記遠心分離工程F後における上清に緩衝液を添加すると共にアルカリを添加してpHが7〜8にて塩析操作を施す塩析工程Gaと、
前記塩析工程Ga後における沈殿物を洗浄し、そして遠心分離操作を施して得られた沈殿物を緩衝液で洗浄する洗浄工程Gbと、
前記洗浄工程Gb後において遠心分離操作を施す遠心分離工程Gcと、
前記遠心分離工程Gc後における沈殿物を洗浄後、遠心分離操作を施し、そして上清に透析操作を施す透析工程I
とを具備することを特徴とするIII型コラーゲン抽出方法によって解決される。
Among them, a washing step Aa for homogenizing human adipose tissue and substantially removing and washing the contained blood,
After the washing step Aa, a washing step Ab for washing with an acidic solution containing a protease inhibitor;
After the washing step Ab, a defatting treatment step B for removing fat contained using an organic solvent,
Pepsin digestion step C, in which pepsin is added to the residue from which fat has been removed and pepsin digestion is performed after the fat removal treatment step B;
A centrifugation step D for subjecting the soluble supernatant after the pepsin digestion step C to a centrifugation operation;
A dialysis step E in which a dialysis operation is performed on the supernatant after the centrifugation step D;
Centrifugation step F in which an acid is added to a precipitate obtained by performing a centrifugation operation after the dialysis step E to perform a centrifugation operation;
A salting-out step Ga in which a buffer solution is added to the supernatant after the centrifugation step F and an alkali is added to perform a salting-out operation at a pH of 7-8;
A washing step Gb for washing the precipitate after the salting-out step Ga, and washing the precipitate obtained by centrifuging with a buffer;
A centrifugal separation step Gc for performing a centrifugal separation operation after the washing step Gb;
Dialysis step I in which the precipitate after the centrifugation step Gc is washed, then subjected to a centrifugal separation operation, and the supernatant is subjected to a dialysis operation.
It is solved by the type III collagen extraction method characterized by comprising.
本発明によれば、ヒト由来のI型コラーゲン或いはIII型コラーゲンを低廉なコストで得ることが出来る。 According to the present invention, human-derived type I collagen or type III collagen can be obtained at low cost.
しかも、自己の体から脂肪吸引などの手段で採取した脂肪組織を原料とした場合、交差感染の恐れも無く、それだけ安全性が高いと考えられる。 Moreover, when the adipose tissue collected from the body by means such as liposuction is used as a raw material, there is no risk of cross-infection and it is considered that the safety is high.
更には、ヒト由来のI型コラーゲン或いはIII型コラーゲンであるから、特に、自己の生体からのI型コラーゲン或いはIII型コラーゲンであるから、注入した場合の生着率は高く、効果も長続きすると考えられる。 Furthermore, since it is type I collagen or type III collagen derived from human beings, especially because it is type I collagen or type III collagen from its own living body, the engraftment rate when injected is high and the effect is thought to last long. It is done.
本発明になるI型コラーゲン抽出方法は、ヒト脂肪組織をタンパク分解酵素で消化させる消化工程Cと、消化工程C後における上清に遠心分離操作を施す遠心分離工程Dと、遠心分離工程D後における上清に透析操作を施す透析工程Eと、
透析工程E後に遠心分離操作を施して得られる沈殿物に酸を添加して遠心分離操作を施す遠心分離工程Fと、遠心分離工程F後における上清に対して塩析操作を施して得られた沈殿物を洗浄後に遠心分離操作を施す遠心分離工程Gと、遠心分離工程G後における上清に透析操作を施す透析工程Hとを具備する。前記遠心分離工程Gは、特に、遠心分離工程F後における上清に緩衝液を添加すると共にアルカリを添加してpHが弱アルカリ状態にて塩析操作を施す塩析工程Gaと、塩析工程Ga後における沈殿物を洗浄し、そして遠心分離操作を施して得られた沈殿物を緩衝液で洗浄する洗浄工程Gbと、洗浄工程Gb後において遠心分離操作を施す遠心分離工程Gcとを具備する。前記消化工程Cの前に、特に、脱血液処理を行う脱血液工程Aを更に具備する。又、前記脱血液工程Aの後で、前記消化工程Cの前に、脱脂肪処理を行う脱脂肪処理工程Bを更に具備する。そして、特に、ヒト脂肪組織をホモジナイズし、含まれている血液を略除去洗浄する洗浄工程Aaと、前記洗浄工程Aaの後、タンパク分解酵素阻害剤を含有する酸性溶液で洗浄する洗浄工程Abと、前記洗浄工程Abの後、有機溶媒を用いて含まれている脂肪分を除去する脱脂肪処理工程Bと、前記脱脂肪処理工程Bの後、脂肪分が除去された残物にペプシンを加えてペプシン消化を施すペプシン消化工程Cと、前記ペプシン消化工程C後における可溶上清に遠心分離操作を施す遠心分離工程Dと、前記遠心分離工程D後における上清に透析操作を施す透析工程Eと、前記透析工程E後に遠心分離操作を施して得られる沈殿物に酸を添加して遠心分離操作を施す遠心分離工程Fと、前記遠心分離工程F後における上清に緩衝液を添加すると共にアルカリを添加してpHが7〜8にて塩析操作を施す塩析工程Gaと、前記塩析工程Ga後における沈殿物を洗浄し、そして遠心分離操作を施して得られた沈殿物を緩衝液で洗浄する洗浄工程Gbと、前記洗浄工程Gb後において遠心分離操作を施す遠心分離工程Gcと、前記遠心分離工程Gc後における上清に透析操作を施す透析工程Hとを具備する。
The type I collagen extraction method according to the present invention includes a digestion step C for digesting human adipose tissue with a proteolytic enzyme, a centrifugation step D for subjecting the supernatant after the digestion step C to centrifugation, and a post-centrifugation step D Dialysis step E for dialysis operation on the supernatant in
Obtained by subjecting the precipitate obtained by centrifuging operation after dialysis step E to acid by adding acid to the centrifuging step F and subjecting the supernatant after centrifuging step F to salting out. A centrifugal separation step G in which a centrifugal separation operation is performed after washing the deposited precipitate, and a dialysis step H in which a dialysis operation is performed on the supernatant after the centrifugal separation step G. The centrifugation step G includes, in particular, a salting-out step Ga in which a buffer solution is added to the supernatant after the centrifugation step F and an alkali is added to perform a salting-out operation in a weakly alkaline state, and a salting-out step A washing step Gb for washing the precipitate after Ga and washing the precipitate obtained by performing a centrifugation operation with a buffer, and a centrifugation step Gc for carrying out a centrifugation operation after the washing step Gb are provided. . Prior to the digestion step C, a blood removal step A for performing blood removal treatment is further provided. Further, after the blood removal step A and before the digestion step C, a defatting treatment step B for performing a defatting treatment is further provided. In particular, a washing step Aa for homogenizing human adipose tissue and substantially removing and washing the contained blood, and a washing step Ab for washing with an acidic solution containing a protease inhibitor after the washing step Aa, After the washing step Ab, a fat removal treatment step B for removing the contained fat using an organic solvent, and after the fat removal treatment step B, pepsin is added to the residue from which the fat content has been removed. Pepsin digestion step C for performing pepsin digestion, centrifugation step D for subjecting the soluble supernatant after the pepsin digestion step C to centrifugation, and dialysis step for subjecting the supernatant after the centrifugation step D to dialysis E, a centrifugation step F in which acid is added to a precipitate obtained by performing a centrifugation operation after the dialysis step E, and a centrifugation operation is performed; and a buffer is added to the supernatant after the centrifugation step F A salting-out process Ga in which a salting-out operation is performed at a pH of 7 to 8 by adding an alkali, and a precipitate obtained after the salting-out process Ga is washed and centrifuged. A washing step Gb for washing with a buffer solution, a centrifugation step Gc for performing a centrifugation operation after the washing step Gb, and a dialysis step H for performing a dialysis operation on the supernatant after the centrifugation step Gc are provided.
本発明になるIII型コラーゲン抽出方法は、本発明になるI型コラーゲン抽出方法の工程の大部分を共通にする。すなわち、最終工程に近い工程までは、同一に行うことが出来る。すなわち、I型コラーゲン抽出方法にあっては、遠心分離工程G後における上清に透析操作を施すのであるが、遠心分離工程G後における沈殿物を洗浄後、遠心分離操作を施し、そして上清に透析操作を施すことによって、III型コラーゲンが得られる。 The type III collagen extraction method according to the present invention shares most of the steps of the type I collagen extraction method according to the present invention. That is, the same process can be performed up to the process close to the final process. That is, in the type I collagen extraction method, the supernatant after the centrifugation step G is subjected to a dialysis operation. The precipitate after the centrifugation step G is washed, then subjected to the centrifugation operation, and the supernatant. A type III collagen is obtained by subjecting to a dialysis operation.
以下、具体的な実施例を挙げて説明する。 Hereinafter, specific examples will be described.
先ず、脂肪吸引技術により採取したヒト大腿部脂肪組織300gをホモジナイズし、精製水にて血液を大まかに除去した。この後、精製水で24時間掛けて洗浄した。 First, 300 g of human thigh adipose tissue collected by a liposuction technique was homogenized, and blood was roughly removed with purified water. Thereafter, it was washed with purified water for 24 hours.
次に、1MのNaClを含む0.05MのTris−HCl(pH7.5)で4日間掛けて洗浄した。この後、更に、精製水で24時間掛けて洗浄した。 Next, it was washed with 0.05 M Tris-HCl (pH 7.5) containing 1 M NaCl for 4 days. Thereafter, it was further washed with purified water for 24 hours.
この後、血清成分を除去する為、タンパク分解酵素阻害剤として4mMのEDTA,2mMのα−トルエンスルホニルフロライド,10mMのN−エチルマレイミド,1μg/mlのPepstatin Aを含む0.5M酢酸溶液で3日間掛けて洗浄した。この後、精製水で24時間掛けて洗浄した。 Thereafter, in order to remove serum components, a 0.5 M acetic acid solution containing 4 mM EDTA, 2 mM α-toluenesulfonyl fluoride, 10 mM N-ethylmaleimide, and 1 μg / ml Pepstatin A as a protease inhibitor is removed. Washed for 3 days. Thereafter, it was washed with purified water for 24 hours.
次いで、上記洗浄した脂肪組織(組織や水分を含めて約108mL)を分液ロートに入れ、そして270mLのメタノールと135mLのクロロホルムを加えて混合した。この後、ロート内の液は二層に分離した。そこで、更に、135mLのクロロホルムを加え、次いで135mLの精製水を加えて混合した。この後、ロート内の液は三層に分離した。三層に分離後、下層を取り除いた。そして、フラッフ層のみを分取した。分取したフラッフ層から溶媒を飛ばし、250mgのペプシンを含む0.5Mの酢酸溶液500mLを加え、24時間掛けてペプシン消化を行わしめた。 Next, the washed adipose tissue (about 108 mL including tissue and water) was placed in a separatory funnel, and 270 mL of methanol and 135 mL of chloroform were added and mixed. Thereafter, the liquid in the funnel was separated into two layers. Therefore, 135 mL of chloroform was further added, and then 135 mL of purified water was added and mixed. Thereafter, the liquid in the funnel was separated into three layers. After separating into three layers, the lower layer was removed. And only the fluff layer was fractionated. The solvent was removed from the collected fluff layer, 500 mL of 0.5 M acetic acid solution containing 250 mg of pepsin was added, and pepsin digestion was performed over 24 hours.
ペプシン消化後の可溶上清に100000g×1時間の超遠心分離操作を施した。この後、上清を0.5M酢酸(0.7MのNaClを含む)で透析し、この後100000g×1時間の超遠心分離操作を施した。 The soluble supernatant after pepsin digestion was subjected to ultracentrifugation at 100,000 g × 1 hour. Thereafter, the supernatant was dialyzed against 0.5 M acetic acid (containing 0.7 M NaCl), and then subjected to ultracentrifugation at 100000 g × 1 hour.
超遠心分離操作の後、沈殿物(I,III型コラーゲンが含まれる)を0.5Mの酢酸に溶解し、この後、再度、100000g×1時間の超遠心分離操作を施した。 After the ultracentrifugation operation, the precipitate (containing type I and type III collagen) was dissolved in 0.5 M acetic acid, and thereafter, ultracentrifugation operation was performed again at 100,000 g × 1 hour.
そして、得られた上清が0.05Mとなるように0.5MのTris−HCl緩衝液(pH7.4)を加え、緩衝能を持たせた上でpHを測定しながら5MのNaOHを加え、pHが7.4のものにした。 Then, add 0.5 M Tris-HCl buffer (pH 7.4) so that the obtained supernatant becomes 0.05 M, and add 5 M NaOH while measuring the pH after providing buffer capacity. The pH was 7.4.
このようにして得られた液に対して4.4Mとなるように塩析(24時間攪拌)を行って得た沈殿物を、0.05MのTris−HCl緩衝液(pH7.5:4.4MのNaClを含む)で24時間掛けて洗浄した。 The precipitate obtained by salting out (stirring for 24 hours) to 4.4 M with respect to the liquid thus obtained was added to a 0.05 M Tris-HCl buffer (pH 7.5: 4. Washed for 24 hours with 4M NaCl).
この洗浄後、100000g×1時間の超遠心分離操作を施した。そして、得られた沈殿物を0.05MのTris−HCl緩衝液(pH7.5:4.4MのNaClを含む)で48時間掛けて洗浄した。 After this washing, an ultracentrifugation operation of 100,000 g × 1 hour was performed. The resulting precipitate was washed with 0.05 M Tris-HCl buffer (pH 7.5: containing 4.4 M NaCl) for 48 hours.
この洗浄後、100000g×1時間の超遠心分離操作を施した。そして、得られた沈殿物を0.05MのTris−HCl緩衝液(pH7.5:2.4MのNaClを含む)で48時間掛けて洗浄した。 After this washing, an ultracentrifugation operation of 100,000 g × 1 hour was performed. The obtained precipitate was washed with 0.05M Tris-HCl buffer (pH 7.5: containing 2.4M NaCl) for 48 hours.
この洗浄後、100000g×1時間の超遠心分離操作を施した。そして、得られた沈殿物を0.05MのTris−HCl緩衝液(pH7.5:1.7MのNaClを含む)で48時間洗浄した。そして、洗浄後、100000g×1時間の超遠心分離操作を施した。そして、得られた上清を0.1Mの酢酸で透析した。次いで、凍結乾燥を行い、25.5mgの試料(I型コラーゲン)を得た。
After this washing, an ultracentrifugation operation of 100,000 g × 1 hour was performed. The resulting precipitate was washed with 0.05 M Tris-HCl buffer (pH 7.5: containing 1.7 M NaCl) for 48 hours. And after washing | cleaning, the ultracentrifugation operation of 100000
前記超遠心分離操作で得られた沈殿物を0.05MのTris−HCl緩衝液(pH7.5:1.0MのNaClを含む)で48時間掛けて洗浄した。 The precipitate obtained by the ultracentrifugation operation was washed with 0.05 M Tris-HCl buffer (pH 7.5: containing 1.0 M NaCl) for 48 hours.
この洗浄後、100000g×1時間の超遠心分離操作を施した。そして、得られた上清を0.1Mの酢酸で透析した。次いで、凍結乾燥を行い、30.4mgの試料(III型コラーゲン)を得た。 After this washing, an ultracentrifugation operation of 100,000 g × 1 hour was performed. The resulting supernatant was dialyzed against 0.1M acetic acid. Subsequently, freeze-drying was performed to obtain 30.4 mg of a sample (type III collagen).
尚、上記工程の概略を図1に示した。 The outline of the above process is shown in FIG.
上記のようにして得られたコラーゲンについて、アミノ酸分析計(日立製835型)でアミノ酸の分析を行った。すなわち、上記試料0.83mgに6Nの塩酸300μLを添加し、110℃で22時間掛けて加水分解し、次いで減圧乾固した。残渣を純水500μLに溶解させ、0.22μmのフィルターで濾過し、濾液を10倍希釈し、アミノ酸分析に供した。その結果を表−1に示す。 The collagen obtained as described above was analyzed for amino acids using an amino acid analyzer (Hitachi Model 835). That is, 300 μL of 6N hydrochloric acid was added to 0.83 mg of the sample, hydrolyzed at 110 ° C. for 22 hours, and then dried under reduced pressure. The residue was dissolved in 500 μL of pure water, filtered through a 0.22 μm filter, and the filtrate was diluted 10 times and subjected to amino acid analysis. The results are shown in Table-1.
表−1
この表−1におけるハイドロキシプロリンはコラーゲンのみに存在するものであるから、抽出された試料はコラーゲンであることが判る。又、ハイドロキシプロリンは、コラーゲンに存在するアミノ酸の約10%であり、表−1も約10%である。
Table-1
Since hydroxyproline in Table-1 is present only in collagen, it can be seen that the extracted sample is collagen. Hydroxyproline is about 10% of amino acids present in collagen, and Table 1 is also about 10%.
次に、上記のようにして得られたI型コラーゲン及びIII型コラーゲンを、各々、電気泳動試料用緩衝液(非還元)及び電気泳動試料用緩衝液(還元)で10mg/mLの濃度に希釈し、SDS化する為、95℃で5分間加温し、非還元型および還元型の電気泳動試料を作成した。そして、電気泳動用ゲル板を開封し、電気泳動装置を組み立て、10%SDSゲルのレーンに試料15μLと分子量マーカー5μLをスポットし、ゲル1枚について20mAで約2時間電気泳動を行った。 Next, the type I collagen and type III collagen obtained as described above were diluted to a concentration of 10 mg / mL with an electrophoresis sample buffer solution (non-reducing) and an electrophoresis sample buffer solution (reduction), respectively. In order to convert to SDS, the sample was heated at 95 ° C. for 5 minutes to prepare non-reduced and reduced electrophoresis samples. Then, the electrophoresis gel plate was opened, the electrophoresis apparatus was assembled, a sample of 15 μL and a molecular weight marker of 5 μL were spotted on a 10% SDS gel lane, and electrophoresis was performed at 20 mA per gel for about 2 hours.
電気泳動終了後、電気泳動装置からゲルを取り出し、下からフィルターペーパー、PVDF膜、ゲル、フィルターペーパーの順に重ねて転写装置を組み立て、15Vで30分間の転写を行った。転写後、PVDF膜を精製水でリンスしてからブロッキング液に浸し、室温で1時間シェイキングしてブロッキングした。この後、TBS−Tweenで10分間シェイキングして洗浄し、各レーン毎に切り分け、各型の一次抗体をTBS−Tweenで2500倍に希釈した液に切り分けたPVDF膜を浸し、4℃で一晩シェイキングした。 After the completion of electrophoresis, the gel was taken out from the electrophoresis apparatus, and the transfer apparatus was assembled from the bottom in the order of filter paper, PVDF membrane, gel, and filter paper, and transferred at 15 V for 30 minutes. After the transfer, the PVDF membrane was rinsed with purified water and then immersed in a blocking solution, followed by shaking at room temperature for 1 hour for blocking. Then, shake with TBS-Tween for 10 minutes to wash, cut into each lane, and soak a PVDF membrane into which each type of primary antibody was cut into a 2500-fold diluted solution with TBS-Tween, and overnight at 4 ° C. Shaking.
翌日、PVDF膜をTBS−Tweenでシェイキングしながら10分間ずつ2回洗浄した。この後、TBS−Tweenで二次抗体を300倍に希釈した液に浸し、室温で2時間シェイキングした。この後、PVDF膜を再びTBS−Tweenでシェイキングしながら10分間ずつ2回洗浄した。この洗浄したPVDF膜をTBS−TweenでSTAV−APcomplexを3000倍に希釈した液(streptavidin 10μL及びbiotinylated Alkaline Phosphatase
10μLをTBS−Tween30mLに加える)に浸し、室温で2時間シェイキングした。この後、TBS−Tweenでシェイキングしながら10分間ずつ2回洗浄した。洗浄後、発色液に浸し、発色するまでシェイキングした。発色後、発色液を捨て、精製水でシェイキングしながら10分間ずつ3回洗浄した。
The next day, the PVDF membrane was washed twice for 10 minutes while shaking with TBS-Tween. Thereafter, the secondary antibody was immersed in a solution diluted 300 times with TBS-Tween and shaken at room temperature for 2 hours. Thereafter, the PVDF membrane was washed twice for 10 minutes while being again shaken with TBS-Tween. This washed PVDF membrane was diluted 3000 times with STBS-AP complex with TBS-Tween (streptavidin 10 μL and biotinylated Alkaline Phosphatase
10 μL was added to 30 mL of TBS-Tween) and shaken at room temperature for 2 hours. Thereafter, the plate was washed twice for 10 minutes while being shaken with TBS-Tween. After washing, it was immersed in a coloring solution and shaken until it developed color. After the color development, the color developing solution was discarded, and the mixture was washed 3 times for 10 minutes while being shaken with purified water.
そして、I型コラーゲン及びIII型コラーゲンに対する一次抗体を反応させたものを図2に示す。 And what reacted the primary antibody with respect to type I collagen and type III collagen is shown in FIG.
この結果、I型コラーゲンに対する一次抗体を反応させたものでは、4個のバンドが確認できた。コラーゲンを変性状態(分子の3本鎖ヘリックス構造が壊れた状態)で泳動すると、α鎖間に架橋結合が有るβ,γ鎖は移動度が小さく、鎖間に架橋が無いα鎖は移動が大きいので、両者は簡単に識別できる。I型コラーゲン分子の鎖組成は、α1鎖(I型)2本とα2鎖(I型)1本で形成されており、泳動のバンドパターン及びバンドの強度比から判断して、最も移動度が大きい1番下に現れているバンドがα2鎖(I型)で、下から2番目の最も強いバンドがα1鎖(I型)であると同定した。 As a result, four bands were confirmed in the case where the primary antibody against type I collagen was reacted. When collagen is migrated in a denatured state (a state in which the three-stranded helix structure of the molecule is broken), β and γ chains with crosslinks between α chains have low mobility, and α chains without crosslinks between chains move. Since it is large, both can be easily identified. Chain composition of type I collagen molecules, alpha 1 chain (I type) 2 and alpha 2 chain (I-type) is formed by one, it is determined from the intensity ratio of the electrophoretic band patterns and band, most mobile The band appearing at the bottom with the highest degree was identified as α 2 chain (type I), and the second strongest band from the bottom was identified as α 1 chain (type I).
III型コラーゲンに対する一次抗体を反応させたものでは、還元型は1個、非還元型は3個のバンドが確認できた。III型コラーゲン分子{α1鎖(III型)}3では、α鎖間にジスルフィド架橋結合が有るので、変性のみでは余り泳動しないが、III型はS−S結合が分子内に存在する為、還元剤でジスルフィド結合を遮断すると、α1鎖(III型)はα1鎖(I型)と同じ移動度を示し、α鎖やβ鎖が生じて来ると考えられる。この結果からも、上記のようにして抽出されたものがI型コラーゲンやIII型コラーゲンであることが判る。 In the case of reacting the primary antibody against type III collagen, one band was confirmed for the reduced type and three bands were observed for the non-reduced type. In type III collagen molecule {α 1 chain (type III)} 3 , since there is a disulfide bridge between α chains, the denaturation alone does not migrate much, but type III has an SS bond in the molecule, When the disulfide bond is blocked with a reducing agent, α 1 chain (type III) shows the same mobility as α 1 chain (type I), and it is considered that α chain and β chain are generated. Also from this result, it can be seen that those extracted as described above are type I collagen and type III collagen.
更に、HPLC法によっても調べた。すなわち、I型コラーゲンおよびIII型コラーゲンの標準品を用意し、液体クロマトグラムに掛けた。又、上記のようにして抽出されたI型コラーゲン及びIII型コラーゲンを液体クロマトグラムに掛けた。その結果、上記のようにして抽出されたものがI型コラーゲン及びIII型コラーゲンであることが判った。 Furthermore, it investigated by HPLC method. That is, standard type I collagen and type III collagen were prepared and subjected to a liquid chromatogram. The type I collagen and type III collagen extracted as described above were applied to a liquid chromatogram. As a result, it was found that those extracted as described above were type I collagen and type III collagen.
Claims (10)
消化工程C後における上清に遠心分離操作を施す遠心分離工程Dと、
遠心分離工程D後における上清に透析操作を施す透析工程Eと、
透析工程E後に遠心分離操作を施して得られる沈殿物に酸を添加して遠心分離操作を施す遠心分離工程Fと、
遠心分離工程F後における上清に対して塩析操作を施して得られた沈殿物を洗浄後に遠心分離操作を施す遠心分離工程Gと、
遠心分離工程G後における上清に透析操作を施す透析工程H
とを具備することを特徴とするI型コラーゲン抽出方法。 Digestion process C for digesting human adipose tissue with proteolytic enzymes;
Centrifugation step D for subjecting the supernatant after the digestion step C to a centrifugation operation,
Dialysis step E for dialysis operation on the supernatant after centrifugation step D,
Centrifugation step F, in which an acid is added to the precipitate obtained by centrifuging after the dialysis step E, and the centrifuging operation is performed.
Centrifugation step G in which the precipitate obtained by subjecting the supernatant after centrifugation step F to salting-out operation is subjected to centrifugation operation after washing,
Dialysis step H in which the supernatant after the centrifugation step G is dialyzed
And a method for extracting type I collagen.
遠心分離工程F後における上清に緩衝液を添加すると共にアルカリを添加してpHが弱アルカリ状態にて塩析操作を施す塩析工程Gaと、
塩析工程Ga後における沈殿物を洗浄し、そして遠心分離操作を施して得られた沈殿物を緩衝液で洗浄する洗浄工程Gbと、
洗浄工程Gb後において遠心分離操作を施す遠心分離工程Gc
とを具備することを特徴とする請求項1のI型コラーゲン抽出方法。 Centrifugation step G
A salting-out step Ga for adding a buffer solution to the supernatant after the centrifugal separation step F and adding an alkali to perform a salting-out operation in a weakly alkaline state;
A washing step Gb for washing the precipitate after the salting-out step Ga, and washing the precipitate obtained by centrifuging with a buffer;
Centrifugation step Gc for performing a centrifugal separation operation after the washing step Gb
The method for extracting type I collagen according to claim 1, comprising:
ことを特徴とする請求項1又は請求項2のI型コラーゲン抽出方法。 The method for extracting type I collagen according to claim 1 or 2, further comprising a blood removal step A for performing blood removal treatment before the digestion step C.
前記脱血液工程Aの後で、消化工程Cの前に脱脂肪処理を行う脱脂肪処理工程B
とを更に具備することを特徴とする請求項1〜請求項3いずれかのI型コラーゲン抽出方法。 A blood removal step A for performing blood removal treatment before the digestion step C;
A defatting process B for performing a defatting process after the blood removal process A and before the digestion process C
The type I collagen extraction method according to any one of claims 1 to 3, further comprising:
前記洗浄工程Aaの後、タンパク分解酵素阻害剤を含有する酸性溶液で洗浄する洗浄工程Abと、
前記洗浄工程Abの後、有機溶媒を用いて含まれている脂肪分を除去する脱脂肪処理工程Bと、
前記脱脂肪処理工程Bの後、脂肪分が除去された残物にペプシンを加えてペプシン消化を施すペプシン消化工程Cと、
前記ペプシン消化工程C後における可溶上清に遠心分離操作を施す遠心分離工程Dと、
前記遠心分離工程D後における上清に透析操作を施す透析工程Eと、
前記透析工程E後に遠心分離操作を施して得られる沈殿物に酸を添加して遠心分離操作を施す遠心分離工程Fと、
前記遠心分離工程F後における上清に緩衝液を添加すると共にアルカリを添加してpHが7〜8にて塩析操作を施す塩析工程Gaと、
前記塩析工程Ga後における沈殿物を洗浄し、そして遠心分離操作を施して得られた沈殿物を緩衝液で洗浄する洗浄工程Gbと、
前記洗浄工程Gb後において遠心分離操作を施す遠心分離工程Gcと、
前記遠心分離工程Gc後における上清に透析操作を施す透析工程H
とを具備することを特徴とするI型コラーゲン抽出方法。 A washing step Aa for homogenizing human adipose tissue and substantially removing and washing the contained blood;
After the washing step Aa, a washing step Ab for washing with an acidic solution containing a protease inhibitor;
After the washing step Ab, a defatting treatment step B for removing fat contained using an organic solvent,
Pepsin digestion step C, in which pepsin is added to the residue from which fat has been removed and pepsin digestion is performed after the fat removal treatment step B;
A centrifugation step D for subjecting the soluble supernatant after the pepsin digestion step C to a centrifugation operation;
A dialysis step E in which a dialysis operation is performed on the supernatant after the centrifugation step D;
Centrifugation step F in which an acid is added to a precipitate obtained by performing a centrifugation operation after the dialysis step E to perform a centrifugation operation;
A salting-out step Ga in which a buffer solution is added to the supernatant after the centrifugation step F and an alkali is added to perform a salting-out operation at a pH of 7-8;
A washing step Gb for washing the precipitate after the salting-out step Ga, and washing the precipitate obtained by centrifuging with a buffer;
A centrifugal separation step Gc for performing a centrifugal separation operation after the washing step Gb;
Dialysis step H in which the supernatant after the centrifugation step Gc is dialyzed
And a method for extracting type I collagen.
消化工程C後における上清に遠心分離操作を施す遠心分離工程Dと、
遠心分離工程D後における上清に透析操作を施す透析工程Eと、
透析工程E後に遠心分離操作を施して得られる沈殿物に酸を添加して遠心分離操作を施す遠心分離工程Fと、
遠心分離工程F後における上清に対して塩析操作を施して得られた沈殿物を洗浄後に遠心分離操作を施す遠心分離工程Gと、
遠心分離工程G後における沈殿物を洗浄後、遠心分離操作を施し、そして上清に透析操作を施す透析工程I
とを具備することを特徴とするIII型コラーゲン抽出方法。 Digestion process C for digesting human adipose tissue with proteolytic enzymes;
Centrifugation step D for subjecting the supernatant after the digestion step C to a centrifugation operation,
Dialysis step E for dialysis operation on the supernatant after centrifugation step D,
Centrifugation step F, in which an acid is added to the precipitate obtained by centrifuging after the dialysis step E, and the centrifuging operation is performed.
Centrifugation step G in which the precipitate obtained by subjecting the supernatant after centrifugation step F to salting-out operation is subjected to centrifugation operation after washing,
After washing the precipitate after the centrifugation step G, the centrifugation operation is performed, and the supernatant is dialyzed.
And a method of extracting type III collagen.
遠心分離工程F後における上清に緩衝液を添加すると共にアルカリを添加してpHが弱アルカリ状態にて塩析操作を施す塩析工程Gaと、
塩析工程Ga後における沈殿物を洗浄し、そして遠心分離操作を施して得られた沈殿物を緩衝液で洗浄する洗浄工程Gbと、
洗浄工程Gb後において遠心分離操作を施す遠心分離工程Gc
とを具備することを特徴とする請求項6のIII型コラーゲン抽出方法。 Centrifugation step G
A salting-out step Ga for adding a buffer solution to the supernatant after the centrifugal separation step F and adding an alkali to perform a salting-out operation in a weakly alkaline state;
A washing step Gb for washing the precipitate after the salting-out step Ga, and washing the precipitate obtained by centrifuging with a buffer;
Centrifugation step Gc for performing a centrifugal separation operation after the washing step Gb
The method for extracting type III collagen according to claim 6, comprising:
ことを特徴とする請求項6又は請求項7のIII型コラーゲン抽出方法。 The method for extracting type III collagen according to claim 6 or 7, further comprising a blood removal step A for performing blood removal treatment before the digestion step C.
前記脱血液工程Aの後で、消化工程Cの前に脱脂肪処理を行う脱脂肪処理工程B
とを更に具備することを特徴とする請求項6〜請求項8いずれかのIII型コラーゲン抽出方法。 A blood removal step A for performing blood removal treatment before the digestion step C;
A defatting process B for performing a defatting process after the blood removal process A and before the digestion process C
The type III collagen extraction method according to any one of claims 6 to 8, further comprising:
前記洗浄工程Aaの後、タンパク分解酵素阻害剤を含有する酸性溶液で洗浄する洗浄工程Abと、
前記洗浄工程Abの後、有機溶媒を用いて含まれている脂肪分を除去する脱脂肪処理工程Bと、
前記脱脂肪処理工程Bの後、脂肪分が除去された残物にペプシンを加えてペプシン消化を施すペプシン消化工程Cと、
前記ペプシン消化工程C後における可溶上清に遠心分離操作を施す遠心分離工程Dと、
前記遠心分離工程D後における上清に透析操作を施す透析工程Eと、
前記透析工程E後に遠心分離操作を施して得られる沈殿物に酸を添加して遠心分離操作を施す遠心分離工程Fと、
前記遠心分離工程F後における上清に緩衝液を添加すると共にアルカリを添加してpHが7〜8にて塩析操作を施す塩析工程Gaと、
前記塩析工程Ga後における沈殿物を洗浄し、そして遠心分離操作を施して得られた沈殿物を緩衝液で洗浄する洗浄工程Gbと、
前記洗浄工程Gb後において遠心分離操作を施す遠心分離工程Gcと、
前記遠心分離工程Gc後における沈殿物を洗浄後、遠心分離操作を施し、そして上清に透析操作を施す透析工程I
とを具備することを特徴とするIII型コラーゲン抽出方法。
A washing step Aa for homogenizing human adipose tissue and substantially removing and washing the contained blood;
After the washing step Aa, a washing step Ab for washing with an acidic solution containing a protease inhibitor;
After the washing step Ab, a defatting treatment step B for removing fat contained using an organic solvent,
Pepsin digestion step C, in which pepsin is added to the residue from which fat has been removed and pepsin digestion is performed after the fat removal treatment step B;
A centrifugation step D for subjecting the soluble supernatant after the pepsin digestion step C to a centrifugation operation;
A dialysis step E in which a dialysis operation is performed on the supernatant after the centrifugation step D;
Centrifugation step F in which an acid is added to a precipitate obtained by performing a centrifugation operation after the dialysis step E to perform a centrifugation operation;
A salting-out step Ga in which a buffer solution is added to the supernatant after the centrifugation step F and an alkali is added to perform a salting-out operation at a pH of 7-8;
A washing step Gb for washing the precipitate after the salting-out step Ga, and washing the precipitate obtained by centrifuging with a buffer;
A centrifugal separation step Gc for performing a centrifugal separation operation after the washing step Gb;
Dialysis step I in which the precipitate after the centrifugation step Gc is washed, then subjected to a centrifugal separation operation, and the supernatant is subjected to a dialysis operation.
And a method of extracting type III collagen.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005317834A JP2007124901A (en) | 2005-11-01 | 2005-11-01 | Method for extracting collagen |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005317834A JP2007124901A (en) | 2005-11-01 | 2005-11-01 | Method for extracting collagen |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2007124901A true JP2007124901A (en) | 2007-05-24 |
Family
ID=38148107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005317834A Pending JP2007124901A (en) | 2005-11-01 | 2005-11-01 | Method for extracting collagen |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2007124901A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010068867A (en) * | 2008-09-16 | 2010-04-02 | Sunmax Biotechnology Co Ltd | Long-acting collagen and method for preparing the same |
CN109731136A (en) * | 2019-01-11 | 2019-05-10 | 四川大学 | A kind of preparation method and application of chondrocyte induction host material |
CN111777680A (en) * | 2020-06-30 | 2020-10-16 | 浙江诸暨聚源生物技术有限公司 | Separation and purification process for improving stability of recombinant collagen solution |
-
2005
- 2005-11-01 JP JP2005317834A patent/JP2007124901A/en active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010068867A (en) * | 2008-09-16 | 2010-04-02 | Sunmax Biotechnology Co Ltd | Long-acting collagen and method for preparing the same |
CN109731136A (en) * | 2019-01-11 | 2019-05-10 | 四川大学 | A kind of preparation method and application of chondrocyte induction host material |
CN109731136B (en) * | 2019-01-11 | 2020-12-25 | 四川大学 | Preparation method and application of cartilage inductive matrix material |
CN111777680A (en) * | 2020-06-30 | 2020-10-16 | 浙江诸暨聚源生物技术有限公司 | Separation and purification process for improving stability of recombinant collagen solution |
CN111777680B (en) * | 2020-06-30 | 2023-11-03 | 浙江诸暨聚源生物技术有限公司 | Separation and purification process for improving stability of recombinant collagen solution |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100676285B1 (en) | Manufactured product using and collagen solution manufacturing method and collagen separation method of animal tissue | |
US5436135A (en) | New preparation of placenta collagen, their extraction method and their applications | |
TWI600660B (en) | Preparation of high purity collagen particles and used thereof | |
EP0419111B1 (en) | Collagen compositions and methods for preparation thereof | |
EP0080956B1 (en) | Process for the industrial preparation of collagenous materials from human placental tissues; human collagenous materials obtained and their use in biomaterials | |
CN105755078A (en) | Preparation method and application of medical grade fish skin collagens | |
KR20140070667A (en) | Native(telopeptide) Placental Collagen Compositions | |
KR101410533B1 (en) | A method for treating material derived from biological tissue | |
KR101158338B1 (en) | Method for isolating atelocollagen | |
KR101760890B1 (en) | Preparing method of Collagen | |
CN105131109A (en) | Collagen extracting method | |
CN113527466A (en) | Preparation method of implant-grade type II collagen | |
CN112852878A (en) | Method for producing recombinant humanized III-type collagen by transgenic silkworms | |
KR101916759B1 (en) | The Method of High-yield and High-purity Manufacturing of Allo-collagen Composition Extracted From Human origin | |
JP2007124901A (en) | Method for extracting collagen | |
CN109550082A (en) | A kind of preparation method of acellular matrix gel | |
JP2013245198A (en) | Method for extracting collagen and method for producing collagen | |
EP0214035B1 (en) | Placenta collagen preparations, method for their extraction and their use | |
JPH0247966B2 (en) | ||
CN113603768B (en) | Preparation method of fish-source collagen | |
KR102502522B1 (en) | Method for extracting extracellular matrix and collagen from adipose tissue | |
KR20150102865A (en) | Biocompatible Collagen and Methods for Preparing the Same | |
JPH09169800A (en) | Hair epithelium-specific protein or derivative therefrom and its production and hair treating agent | |
CN1795204A (en) | Method for the extraction of deer antler | |
CN117582556B (en) | Method for reducing antigenicity of biomedical material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090218 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090415 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090819 |